EN DE
Watch Cosmos Health Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cosmos Health Inc. (COSM) fair value: what the stock is really worth

As of Oct 20, 2026: fair value (intrinsic value) of Cosmos Health Inc. stock $0.64, price $0.33, upside +92.9%, quality 30 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Based in Greece · ISIN US2214133058

CH Cosmos Health Inc. logo Thin data Oct 4, 2026

Cosmos Health Inc.

COSM · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

The stock costs 48% less than our calculation considers fair.

Fair value $0.6375 · Strongly undervalued (+92.9%)
Low debt
Mixed Growth (revenue 5y +3.3 %/yr in USD)
Quality 30/100
Loss-making · -33.1% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 6/100 · thin data
Thin data
⚠ Dilution
Watch Cosmos Health Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.01 $0.0730 Fair Value $0.6375 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

60‑month range $0.0730 – $23.01 · fair‑value band $0.3740 – $0.8330 · the $0.3305 price screens below the $0.6375 fair value. Dashed = 300-day average. As of Oct 4, 2026.

Follow Cosmos Health in your weekly email

Every Wednesday you see whether Cosmos Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus.

Show moreShow less

The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names.

It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).

In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand.

It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

Stock analysis

Cosmos Health Inc. (COSM) currently trades at $0.3305, while our model-based Fair Value estimate is $0.6375, implying the stock looks roughly 48.2% undervalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of $0.7000 per share, and 2 of the 3 models we run sit above the $0.3305 price.

Bear case: the Asset-Based group reads lowest at $0.0700, and 1 of the 3 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.3740 (bear) to $0.8330 (bull), the price of $0.3305 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cosmos Health Inc. reported revenue of $65.3M in FY2025 versus $56.2M in FY2021, a compound +3.8%/yr. Reported net income was −$19.1M in FY2025.

Key figures

Market cap $33.3M Micro · P/S ratio 0.52 · EPS (TTM) $−0.6700 · Net margin −33.1% · Return on equity −104% · Return on assets (EBIT) −21.4% · Operating margin −15.4% · Revenue (TTM) $73.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 69% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 34% fair-value upside, at 93%, COSM screens cheaper than that median.

Fair Value models

Bear $0.3740 Fair Value $0.6375 Bull $0.8330
Price $0.3305 · Upside +92.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Gordon GGM $0.4400 $0.7500 $0.9800 66
DDM Multi-Stage $0.4400 $0.7000 $0.8000 65
NCAV (Graham) $0.0500 $0.0700 $0.1100 53
All 3 models by family
Dividend Discount
Gordon GGM $0.4400 $0.7500 $0.9800 66
DDM Multi-Stage $0.4400 $0.7000 $0.8000 65
Asset-Based
NCAV (Graham) $0.0500 $0.0700 $0.1100 53

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 21
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 44
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 11/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2020 (pandemic)
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.9% (2020) → −25.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch COSM, get fair value alerts →

Compare Cosmos Health Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 76 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside +92.9% · Top 25%
Profitability
Return on assets −29.2% · Bottom 25%
Net margin (12 months) −33.1% · Bottom 25%
Operating margin (12 months) −15.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 28.8% · Top 25%
Dividend yield (12 months) 16.2% · Top 25%
Balance sheet
Debt / equity 0.32× · Above median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 1.81× · Priciest 25%
P/S (12 months) 0.45× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 42
FUTURE (revenue growth)100 · sector 15
PAST (return on equity)0 · sector 27
HEALTH (low debt)84 · sector 96
DIVIDEND (yield)100 · sector 57

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$15.13 HK$55.95 +270% vs COSM
Shanghai Pharmaceuticals Holding 601607 ¥16.70 ¥42.67 +156% vs COSM
Jointown Pharmaceutical Group 600998 ¥4.93 ¥11.56 +134% vs COSM
China National Medicines Corporation 600511 ¥27.17 ¥58.47 +115% vs COSM
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.88 ¥26.64 +34% vs COSM
Henry Schein, Inc HSIC $84.01 $76.77 −9% vs COSM
McKesson Corporation MCK $1,010 $822.74 −19% vs COSM
Galenica AG GALE CHF 85.50 CHF 61.79 −28% vs COSM
Cardinal Health, Inc CAH $252.65 $162.84 −36% vs COSM
Cencora, Inc COR $340.00 $215.20 −37% vs COSM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cosmos Health Inc. · Fair Value
$0.6375 +48%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cosmos Health Inc. Fair Value". https://www.fairvalue-calculator.com/stock/COSM

Frequently asked questions

Is Cosmos Health Inc. (COSM) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $0.6375 versus a price of $0.3305, about +93% upside (undervalued).
What is the fair value of COSM?
Our model-based fair value for Cosmos Health Inc. is $0.6375 (as of Oct 4, 2026), built from audited fundamentals. The current price: $0.3305.
What is the quality score of COSM?
Cosmos Health Inc. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cosmos Health Inc. (COSM)?
Our model-based price target is the fair value of $0.6375 (as of Oct 4, 2026) from 3 valuation models. Cautious scenario $0.3740, optimistic scenario $0.8330. It is a calculation from audited fundamentals, not an analyst target.
What is the Cosmos Health Inc. stock forecast for 2026?
Our models put fair value at $0.6375, about +93% upside versus a price of $0.3305 (undervalued). Cautious scenario $0.3740, optimistic scenario $0.8330. The calculation is refreshed regularly with new filings.
What is the revenue of Cosmos Health Inc. (COSM)?
Cosmos Health Inc. reported trailing-twelve-month revenue of about $73.7M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Cosmos Health Inc. (COSM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cosmos Health Inc. it is $0.6375 per share (as of Oct 4, 2026), against a price of $0.3305. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Cosmos Health Inc. stock overvalued or undervalued in 2026?
As of Oct 4, 2026, COSM trades below its calculated fair value: price $0.3305, fair value $0.6375, a gap of about +93% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COSM?
No. The price is what the market pays today ($0.3305); the fair value is what the company's own numbers justify ($0.6375). For Cosmos Health Inc. the two are $0.3070 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cosmos Health Inc. worth?
The market values Cosmos Health Inc. at about $33.3M (market capitalisation, as of Oct 4, 2026). Per share that is $0.3305; our models calculate a fair value of $0.6375 per share.
What do the bullish and bearish scenarios say about COSM?
Our models span a range for Cosmos Health Inc.: cautious scenario $0.3740, base $0.6375, optimistic $0.8330 per share (as of Oct 4, 2026, price $0.3305). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cosmos Health Inc. (COSM)?
Balance-sheet figures for Cosmos Health Inc. (as of Oct 4, 2026): return on equity −104.0%, debt of 0.32 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is COSM from its 52-week high?
Cosmos Health Inc. trades at $0.3305, about 69% below its 52-week high of $1.05 and 92% above the low of $0.1720 (as of Oct 20, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6375 is for.
Which stocks are comparable to Cosmos Health Inc.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cosmos Health Inc. stock attractive at the current price?
The data as of Oct 4, 2026: price $0.3305, calculated fair value $0.6375 (+93%), Quality Score 30/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COSM calculated?
We run Cosmos Health Inc. through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6375, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Cosmos Health Inc. currently trades 48 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cosmos Health Inc. (COSM)?
The closing price on Oct 20, 2026 was $0.3305. Our model-based fair value is $0.6375, about +93% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cosmos Health Inc. right now?
The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.3740). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3740 to $0.8330) leaves room in how you read the outcome.

Key figures of Cosmos Health Inc.

How large is the market capitalisation of Cosmos Health Inc. (COSM)?
The market capitalisation of Cosmos Health Inc. is $33.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cosmos Health Inc. (COSM)?
The price-to-sales ratio of Cosmos Health Inc. is 0.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cosmos Health Inc. (COSM)?
Earnings per share at Cosmos Health Inc. are $−0.6700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cosmos Health Inc. (COSM)?
The net margin of Cosmos Health Inc. is −33.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cosmos Health Inc. (COSM)?
The return on equity (ROE) of Cosmos Health Inc. is −104% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cosmos Health Inc. (COSM)?
On an EBIT basis the return on assets of Cosmos Health Inc. is −21.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cosmos Health Inc. (COSM)?
The operating margin of Cosmos Health Inc. is −15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cosmos Health Inc. (COSM)?
Revenue at Cosmos Health Inc. is growing +28.8% versus a year earlier (3y avg +9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cosmos Health Inc. (COSM) generate?
The free cash flow of Cosmos Health Inc. is −$8.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cosmos Health Inc. (COSM) carry?
The net debt of Cosmos Health Inc. is $19.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cosmos Health Inc. in the live analysis

One click puts Cosmos Health Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.